petosemtamab   Click here for help

GtoPdb Ligand ID: 14238

Synonyms: MCLA-158 | MCLA158
Compound class: Antibody
Comment: Petosemtamab (MCLA-158) is a bispecific epidermal growth factor receptor (EGFR)/leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) IgG1 monoclonal antibody that was designed for anti-tumour potential [3-4]. In sensitive cancer cells petosemtamab promotes internalisation and degradation of EGFR, inhibits EGFR signalling and engages an anti-tumour immune response via LGR5. It has enhanced ADCC activity against EGFR-driven head and neck squamous cell carcinoma (HNSCC) LGR5-expressing cancer stem cells [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Petosemtamab (MCLA-158) was progressed to late stage clinical development for potential to treat head and neck squamous cell carcinoma (HNSCC) [5]. It was granted FDA Breakthrough Therapy Designation for this indication in early 2025. In October 2026, Genmab announced statistically significant efficacy in their phase 3 LiGeR-HN1 trial (petosemtamab and pembrolizumab, versus pembrolizumab alone) in patients with PD-L1 +ve HNSCC [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03526835 A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors Phase 1/Phase 2 Interventional Merus N.V. 1
NCT06496178 A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients Phase 3 Interventional Merus N.V. 5
NCT06525220 A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) Phase 3 Interventional Merus N.V. The LiGeR-HN1 trial 2,5
NCT07702032 Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) Phase 3 Interventional Genmab The LiGeR-CRC1 trial
NCT07775287 Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Phase 3 Interventional Genmab The LiGeR-CRC2 trial